Literature DB >> 23105273

Clinical and oncological significance of aberrant Fas (APO-1/CD95) isoform expression in adult T-cell leukemia.

S Kamihira1, Y Yamada, T Maeda.   

Abstract

Fas (APO-1/CD95), a transmembrane death receptor mediating apoptosis, can induce cell deathin vivo andin vitro of not only normal T-cells but also leukemic T-cells. This indicates that dysfunction in T-cell apoptosis may influence the natural history of the T-cell neoplasms, such as adult T-cell leukemia (ATL) caused by the retrovirus HTLV-1. Fas is ubiquitous, and down-regulated or mutated Fas has been widely detected in tumor cells that escape from elimination via Fas-mediated apoptosis. De novo fresh ATL cells and cell lines derived from the de novo cells, however, express Fas abundantly on the cell surface and are susceptible to Fas ligand and agonistic agents. On the other hand, there are two types of Fas gene transcripts, full-length and alternatively splicing truncated forms corresponding to membrane and soluble Fas isoforms, respectively. Focusing on membrane and soluble Fas isoforms and ATL pathology mediated by apoptosis, this paper reviews and discusses our ATL cases and ATL cell lines, which provide useful "experiments of nature" for understanding the role of Fas-mediated apoptosis in tumor biology.

Entities:  

Keywords:  ATL; Fas (APO-1/CD95); HTLV-1; apoptosis; mutation

Year:  2000        PMID: 23105273      PMCID: PMC3454065          DOI: 10.1007/BF02867549

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  32 in total

1.  Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.

Authors:  J Drappa; A K Vaishnaw; K E Sullivan; J L Chu; K B Elkon
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

2.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.

Authors:  N Itoh; S Yonehara; A Ishii; M Yonehara; S Mizushima; M Sameshima; A Hase; Y Seto; S Nagata
Journal:  Cell       Date:  1991-07-26       Impact factor: 41.582

3.  Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis.

Authors:  U von Reyher; J Sträter; W Kittstein; M Gschwendt; P H Krammer; P Möller
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

4.  Qualitative and quantitative characterization of Fas (APO-1/CD95) on leukemic cells derived from patients with B-cell neoplasms.

Authors:  K Tsuruda; Y Yamada; Y Hirakata; K Sugahara; T Maeda; S Atogami; M Tomonaga; S Kamihira
Journal:  Leuk Res       Date:  1999-02       Impact factor: 3.156

5.  Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis.

Authors:  S Kamihira; Y Yamada; M Tomonaga; K Sugahara; K Tsuruda
Journal:  Br J Haematol       Date:  1999-12       Impact factor: 6.998

6.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule.

Authors:  J Cheng; T Zhou; C Liu; J P Shapiro; M J Brauer; M C Kiefer; P J Barr; J D Mountz
Journal:  Science       Date:  1994-03-25       Impact factor: 47.728

7.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.

Authors:  K J Van Zee; T Kohno; E Fischer; C S Rock; L L Moldawer; S F Lowry
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

Review 8.  The Fas death factor.

Authors:  S Nagata; P Golstein
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

9.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.

Authors:  F Rieux-Laucat; F Le Deist; C Hivroz; I A Roberts; K M Debatin; A Fischer; J P de Villartay
Journal:  Science       Date:  1995-06-02       Impact factor: 47.728

10.  Fas gene mutation in the progression of adult T cell leukemia.

Authors:  T Maeda; Y Yamada; R Moriuchi; K Sugahara; K Tsuruda; T Joh; S Atogami; K Tsukasaki; M Tomonaga; S Kamihira
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.